Last reviewed · How we verify
MK0733 / Duration of Treatment: 18 Weeks
MK0733 / Duration of Treatment: 18 Weeks is a NK1 receptor antagonist Small molecule drug developed by Organon and Co. It is currently in Phase 3 development for Chemotherapy-induced nausea and vomiting (CINV), Postoperative nausea and vomiting (PONV).
MK0733 is a selective antagonist of the neurokinin-1 (NK1) receptor that blocks substance P signaling in the central nervous system.
MK0733 is a selective antagonist of the neurokinin-1 (NK1) receptor that blocks substance P signaling in the central nervous system. Used for Chemotherapy-induced nausea and vomiting (CINV), Postoperative nausea and vomiting (PONV).
At a glance
| Generic name | MK0733 / Duration of Treatment: 18 Weeks |
|---|---|
| Sponsor | Organon and Co |
| Drug class | NK1 receptor antagonist |
| Target | NK1 receptor (neurokinin-1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Oncology / Pain Management |
| Phase | Phase 3 |
Mechanism of action
The drug works by binding to and blocking NK1 receptors, which are involved in pain transmission and emetic (nausea/vomiting) pathways. By antagonizing these receptors, MK0733 may reduce pain perception and chemotherapy-induced nausea and vomiting (CINV). This mechanism has been explored in various pain and antiemetic indications.
Approved indications
- Chemotherapy-induced nausea and vomiting (CINV)
- Postoperative nausea and vomiting (PONV)
Common side effects
- Headache
- Dizziness
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MK0733 / Duration of Treatment: 18 Weeks CI brief — competitive landscape report
- MK0733 / Duration of Treatment: 18 Weeks updates RSS · CI watch RSS
- Organon and Co portfolio CI
Frequently asked questions about MK0733 / Duration of Treatment: 18 Weeks
What is MK0733 / Duration of Treatment: 18 Weeks?
How does MK0733 / Duration of Treatment: 18 Weeks work?
What is MK0733 / Duration of Treatment: 18 Weeks used for?
Who makes MK0733 / Duration of Treatment: 18 Weeks?
What drug class is MK0733 / Duration of Treatment: 18 Weeks in?
What development phase is MK0733 / Duration of Treatment: 18 Weeks in?
What are the side effects of MK0733 / Duration of Treatment: 18 Weeks?
What does MK0733 / Duration of Treatment: 18 Weeks target?
Related
- Drug class: All NK1 receptor antagonist drugs
- Target: All drugs targeting NK1 receptor (neurokinin-1 receptor)
- Manufacturer: Organon and Co — full pipeline
- Therapeutic area: All drugs in Oncology / Pain Management
- Indication: Drugs for Chemotherapy-induced nausea and vomiting (CINV)
- Indication: Drugs for Postoperative nausea and vomiting (PONV)
- Compare: MK0733 / Duration of Treatment: 18 Weeks vs similar drugs
- Pricing: MK0733 / Duration of Treatment: 18 Weeks cost, discount & access